Medical research

Pfizer and BioNTech to Supply the European Union with 100 Million Additional Doses of COMIRNATY®

Retrieved on: 
Tuesday, December 29, 2020

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they will supply an additional 100 million doses of COMIRNATY, the companies COVID-19 Vaccine, to the 27 European Union (EU) member states in 2021.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they will supply an additional 100 million doses of COMIRNATY, the companies COVID-19 Vaccine, to the 27 European Union (EU) member states in 2021.
  • This announcement is a result of the European Commissions decision to exercise its option to purchase an additional 100 million doses under its Advanced Purchase Agreement signed on November 11, 2020 .
  • The additional 100 million doses will be delivered in 2021 supporting the vaccination campaigns which started two days ago in all 27 member states.
  • Pfizer and BioNTech announced on November 11, 2020, that they reached an agreement with the European Commission to supply 200 million doses, with an option for the European Commission to request an additional 100 million doses.

These Are the Top 20 Best Places to Work in Middle East 2020

Retrieved on: 
Tuesday, December 29, 2020

Gulf Business Machines, Lundbeck, Novo Nordisk, Qetaifan projects, AstraZeneca, MSD, Johnson & Johnson, Teleperformance and Ooredoo are among the list of the top best places to work in Middle East 2020 according to the prestigious Best Places To Work certification program.

Key Points: 
  • Gulf Business Machines, Lundbeck, Novo Nordisk, Qetaifan projects, AstraZeneca, MSD, Johnson & Johnson, Teleperformance and Ooredoo are among the list of the top best places to work in Middle East 2020 according to the prestigious Best Places To Work certification program.
  • The program recently compiled its annual list of the 20 Best Places To Work in Middle East ranking based on the assessment of over 250 organizations across the region.
  • Findings from this year program show how well companies have adapted to the challenges brought about by the COVID-19 pandemic.
  • This years list of Best Places To Work in Middle East represents great diversity in terms of industries, size and countries.

Houston Methodist implements Syllable's AI voice solution technology to enhance patient experience by reducing call volume during COVID-19

Retrieved on: 
Tuesday, December 29, 2020

The latest Syllable voice assistant technology helps manage inbound patient call volume related to the COVID-19 vaccine , which was recently given emergency use authorization by the FDA.

Key Points: 
  • The latest Syllable voice assistant technology helps manage inbound patient call volume related to the COVID-19 vaccine , which was recently given emergency use authorization by the FDA.
  • In March, Houston Methodist worked with Syllable to shift messaging to address the influx of patient inquiries related to COVID-19 testing and scheduling appointments.
  • Through use of its website chatbot, Syllable and Houston Methodist were able to immediately address patients, triaging eligible candidates for plasma donation.
  • Together we are creating the shortest distance between the patient and the care the patient needs."

Moderna to Present at the Goldman Sachs 13th Annual Healthcare CEOs Unscripted Conference: A View from the Top

Retrieved on: 
Tuesday, December 29, 2020

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Stphane Bancel, Chief Executive Officer, will participate virtually in the Goldman Sachs 13th Annual Healthcare CEOs Unscripted Conference on January 5th, 2021 at 8:00 a.m.

Key Points: 
  • Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Stphane Bancel, Chief Executive Officer, will participate virtually in the Goldman Sachs 13th Annual Healthcare CEOs Unscripted Conference on January 5th, 2021 at 8:00 a.m.
  • A live webcast will be available under Events and Presentations in the Investors section of the Moderna website at investors.modernatx.com .
  • A replay of the webcast will be archived on Modernas website for 90 days following the presentation.
  • Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients.

Sheremetyevo International Airport Manages First Shipment Of Sputnik V Vaccine To Argentina

Retrieved on: 
Monday, December 28, 2020

MOSCOW, Dec. 28, 2020 /PRNewswire/ -- Sheremetyevo International Airport once again managed the logistics of delivering the Sputnik V coronavirus vaccine on December 24 when the Russian Direct Investment Fund shipped the first batch of 300,000 doses of the vaccine to Argentina through Sheremetyevo's cargo facilities.

Key Points: 
  • MOSCOW, Dec. 28, 2020 /PRNewswire/ -- Sheremetyevo International Airport once again managed the logistics of delivering the Sputnik V coronavirus vaccine on December 24 when the Russian Direct Investment Fund shipped the first batch of 300,000 doses of the vaccine to Argentina through Sheremetyevo's cargo facilities.
  • This delivery of the world's first coronavirus vaccine is first of 10 million doses the Government of Argentina will receive.
  • The supply of 300,000 doses to Argentina is one of the largest single shipments of a COVID vaccine to any country in Latin America.
  • Argentina is the first country in Latin America to officially authorize the use of Sputnik V vaccine.

Introducing COMIRNATY®, the EU Brand Name for Pfizer & BioNTech's COVID-19 Vaccine, Developed by Brand Institute

Retrieved on: 
Monday, December 28, 2020

Shortly after, it was included in the conditional marketing authorization published by the European Medicines Agency (EMA).

Key Points: 
  • Shortly after, it was included in the conditional marketing authorization published by the European Medicines Agency (EMA).
  • The approval of the brand name by other global regulatory agencies will follow their respective guidelines, policies and procedures.
  • The COVID-19 vaccine's proposed nonproprietary name (pINN), tozinameran (toe zi na' mer an), was also developed by Brand Institute and its wholly owned subsidiary, Drug Safety Institute .
  • With a portfolio of over 3,300 marketed healthcare names for close to 950 clients, Brand Institute is the global leader in pharmaceutical and healthcare related name development.

Introducing COMIRNATY®, the EU Brand Name for Pfizer & BioNTech's COVID-19 Vaccine, Developed by Brand Institute

Retrieved on: 
Monday, December 28, 2020

Shortly after, it was included in the conditional marketing authorization published by the European Medicines Agency (EMA).

Key Points: 
  • Shortly after, it was included in the conditional marketing authorization published by the European Medicines Agency (EMA).
  • The approval of the brand name by other global regulatory agencies will follow their respective guidelines, policies and procedures.
  • The COVID-19 vaccine's proposed nonproprietary name (pINN), tozinameran (toe zi na' mer an), was also developed by Brand Institute and its wholly owned subsidiary, Drug Safety Institute .
  • With a portfolio of over 3,300 marketed healthcare names for close to 950 clients, Brand Institute is the global leader in pharmaceutical and healthcare related name development.

Aprea Therapeutics Announces Results of Primary Endpoint from Phase 3 Trial of Eprenetapopt in TP53 Mutant Myelodysplastic Syndromes (MDS)

Retrieved on: 
Monday, December 28, 2020

The trial did not meet the predefined primary endpoint of complete remission (CR) rate.

Key Points: 
  • The trial did not meet the predefined primary endpoint of complete remission (CR) rate.
  • The combination of eprenetapopt with AZA appeared well-tolerated, with an adverse event profile that was similar to the Companys prior Phase 2 clinical trials.
  • Subsequent analyses of the trial data, including secondary endpoints, will be conducted as the duration of patient follow-up increases.
  • The Phase 3 trial enrolled 154 TP53 mutant MDS patients, randomized 1:1 to either the eprenetapopt with AZA arm or the AZA alone arm.

iBio Appoints Dr. Martin B. Brenner as Chief Scientific Officer

Retrieved on: 
Monday, December 28, 2020

BRYAN, Texas, Dec. 28, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (iBio or the Company), a biotech innovator and biologics contract manufacturing organization, today announced the appointment of Martin B. Brenner, DVM, Ph.D., as its Chief Scientific Officer (CSO), effective January 18, 2020.

Key Points: 
  • BRYAN, Texas, Dec. 28, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (iBio or the Company), a biotech innovator and biologics contract manufacturing organization, today announced the appointment of Martin B. Brenner, DVM, Ph.D., as its Chief Scientific Officer (CSO), effective January 18, 2020.
  • We are thrilled to have Dr. Brenner join our team, said Tom Isett, Chairman & CEO of iBio.
  • Given his prior experience leading organizations with novel protein expression platforms to build proprietary product pipelines, Dr. Brenner should be uniquely suited to assist iBio with a similar transformation.
  • Earlier in his career, Dr. Brenner was the Senior Director and Head of cardiovascular, renal, and metabolism (CVRM) biosciences at AstraZeneca.

IMV Reports Update on COVID-19 Vaccine Program

Retrieved on: 
Monday, December 28, 2020

IMV Inc. (Nasdaq: IMV; TSX: IMV) (the Company), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today reported update on the development of its vaccine candidate, DPX-COVID-19, for the prevention of COVID-19 infection caused by the novel coronavirus SARS-CoV-2.

Key Points: 
  • IMV Inc. (Nasdaq: IMV; TSX: IMV) (the Company), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today reported update on the development of its vaccine candidate, DPX-COVID-19, for the prevention of COVID-19 infection caused by the novel coronavirus SARS-CoV-2.
  • Our vaccine is one of the first peptide-based targeted vaccines in development for COVID-19.
  • IMV is pioneering a new class of cancer-targeted immunotherapies and vaccines based on the Companys proprietary drug delivery platform.
  • IMV is also developing a DPX-based vaccine to fight against COVID-19.